<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oxaliplatin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oxaliplatin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Oxaliplatin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11021" href="/d/html/11021.html" rel="external">see "Oxaliplatin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13031" href="/d/html/13031.html" rel="external">see "Oxaliplatin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709183"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity/Anaphylactic reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious and fatal hypersensitivity adverse reactions, including anaphylaxis, can occur with oxaliplatin within minutes of administration and during any cycle. Oxaliplatin is contraindicated in patients with hypersensitivity reactions to oxaliplatin and other platinum-based drugs. Immediately and permanently discontinue oxaliplatin for hypersensitivity reactions and administer appropriate treatment for management of the hypersensitivity reaction.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867776"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>TARO-Oxaliplatin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F204285"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Alkylating Agent;</li>
<li>
                        Antineoplastic Agent, Platinum Analog</li></ul></div>
<div class="block doa drugH1Div" id="F204263"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Oxaliplatin is associated with a moderate emetic potential and is known to cause delayed nausea and vomiting; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>). Avoid oxaliplatin in patients with congenital long QT syndrome. Correct hypokalemia and hypomagnesemia prior to and during oxaliplatin treatment.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="70eab7a6-b58d-487c-8f61-229bd7e67a11">Biliary tract cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Biliary tract cancer, advanced (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GEMOX regimen:</i>
<b>IV:</b> 100 mg/m<sup>2</sup> on day 2 every 2 weeks (in combination with gemcitabine) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15319238']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15319238'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Modified GEMOX regimen:</i>
<b>IV:</b> 80 mg/m<sup>2</sup> on days 1 and 8 every 3 weeks (in combination with gemcitabine) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20855823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20855823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CAPOX regimen:</i>
<b>IV:</b> 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18182984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18182984'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOX regimen:</i>
<b>IV: </b>85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil and leucovorin) for up to 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33798493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33798493'])">Ref</a></span>) or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12232749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12232749'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75e3c27a-8f51-4a37-9164-c56fb95ce32b">Chronic lymphocytic leukemia, fludarabine refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia, fludarabine refractory (off-label use):</b> OFAR regimen: <b>IV:</b> 25 mg/m<sup>2 </sup>on days 1 to 4 every 4 weeks (in combination with fludarabine, cytarabine, and rituximab) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18182662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18182662'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1bd2454-dab1-485c-8831-642cfd26eb29">Colorectal cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer, advanced: IV:</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with infusional fluorouracil/leucovorin) until disease progression or unacceptable toxicity.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Colorectal cancer, advanced (off-label dosing/combinations):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>FOLFOX regimens:</i>
<b> IV:</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil/leucovorin and bevacizumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18421053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18421053'])">Ref</a></span>) <b>or</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil/leucovorin and cetuximab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28632865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28632865'])">Ref</a></span>) <b>or</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil/leucovorin and panitumumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20921465','lexi-content-ref-24718886']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20921465','lexi-content-ref-24718886'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>FOLFOXIRI regimens:</i>
<b>IV:</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil/leucovorin/irinotecan) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17470860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17470860'])">Ref</a></span>) <b>or</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil/leucovorin/irinotecan and bevacizumab) for up to 12 cycles, followed by fluorouracil/leucovorin and bevacizumab maintenance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26338525','lexi-content-ref-25337750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26338525','lexi-content-ref-25337750'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CAPOX regimens:</i>
<b> IV:</b> 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18421053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18421053'])">Ref</a></span>) <b>or</b> 130 mg/m<sup>2</sup> on day 1 every 3 weeks in combination with capecitabine and bevacizumab until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18421054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18421054'])">Ref</a></span>) <b>or</b> 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine and panitumumab) for at least 6 cycles or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29855806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29855806'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f69499f6-18a3-4c4e-a6e9-cc678955b8d5">Colon cancer, stage III, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colon cancer, stage III, adjuvant therapy:</b>
<b>IV:</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with infusional fluorouracil/leucovorin) for up to 12 cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Colon cancer, adjuvant therapy (off-label dosing/combinations):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>FLOX regimen:</i>
<b>IV:</b> 85 mg/m<sup>2</sup> on days 1, 15, and 29 of an 8-week treatment cycle (in combination with fluorouracil/leucovorin) for 3 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17470851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17470851'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>CAPOX regimen:</i>
<b>IV:</b> 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine) for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21383294']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21383294'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Adjuvant therapy duration; completely resected stage III colon cancer (off label):</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Low risk (T1, T2, or T3 and N1):</i> A duration of therapy of 3 or 6 months of oxaliplatin (when used in combination with fluoropyrimidine-based therapy) may be offered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30986117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30986117'])">Ref</a></span>). A pooled analysis of 6 phase III studies demonstrated non-inferiority (based on 3-year disease-free survival) with a 3-month (compared to a 6-month) adjuvant oxaliplatin-capecitabine (CAPOX) treatment duration in the subgroup of patients with T1, T2, or T3 and N1 stage III colon cancer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29590544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29590544'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>High risk (T4 and/or N2):</i> A duration of therapy of 6 months of oxaliplatin (when used in combination with fluoropyrimidine-based therapy) should be offered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30986117']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30986117'])">Ref</a></span>). In a pooled analysis of 6 phase III studies, superior disease-free survival has been demonstrated with 6 months (compared to 3 months) of adjuvant FOLFOX therapy in the subgroup of patients with T4 and/or N2 stage III colon cancer. Among patients treated with CAPOX, disease-free survival was similar between patients treated for 3 months compared to 6 months in the subgroup of patients with T4 and/or N2 stage III colon cancer, although statistical noninferiority was not proven (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29590544']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29590544'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e50dc227-3f50-48ae-aba5-898bd2fb9c33">Esophageal cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CAPOX regimen (advanced or metastatic esophageal or gastroesophageal junction adenocarcinoma):</i>
<b>IV:</b> 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine and nivolumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34102137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34102137'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLOT regimen (advanced, resectable </i>
<i>gastroesophageal junction adenocarcinoma)</i>: <b>IV: </b>85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and docetaxel) for 4 preoperative and 4 postoperative cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30982686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30982686'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOX4 regimen (chemoradiotherapy for locally advanced, recurrent, or metastatic disease</i>
<i>)</i>: <b>IV: </b>85 mg/m<sup>2</sup> on day 1 every 2 weeks, in combination with fluorouracil and leucovorin and radiation for 3 cycles, then without radiation for 3 more cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20940718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20940718'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>mFOLFOX regimen (advanced or metastatic esophageal or gastroesophageal junction adenocarcinoma):</i>
<b>IV:</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and nivolumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34102137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34102137'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLOT regimen (locally advanced, recurrent, or metastatic disease):</i>
<b>IV:</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and docetaxel) for up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18669868']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18669868'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose optimization for advanced, palliative treatment in frail and/or elderly patients: </i>A dose optimization study that examined 60%, 80%, or 100% of a 130 mg/m<sup>2</sup> dose once every 21 days (in combination with capecitabine) found that the 60% dose was not inferior (for progression-free survival) and had less toxicity compared to the full dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hall.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hall.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment of advanced or metastatic disease:</i> Treatment with doublet, rather than triplet, chemotherapy may be preferred in the palliative setting due to increased toxicity (without clear benefit) with triplet regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35914638']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35914638'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0941e1ee-82d0-48a1-a4ca-aa05a3115959">Gastric cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Adjuvant therapy: </i>
<b>IV:</b> 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine) for 8 cycles following D2 gastrectomy in patients who did not receive preoperative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22226517']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22226517'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CAPOX regimen (locally advanced, unresectable disease, or advanced or metastatic disease):</i>
<b>IV:</b> 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine, pembrolizumab, and trastuzumab for HER2-positive gastric or gastroesophageal adenocarcinoma) until disease progression or unacceptable toxicity or (in patients without disease progression) for up to 24 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34912120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34912120'])">Ref</a></span>) <b>or</b> 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine and nivolumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34102137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34102137'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLOT regimen (locally advanced, resectable disease)</i>: <b>IV: </b>85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and docetaxel) for 4 preoperative and 4 postoperative cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30982686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30982686'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>mFOLFOX regimen (advanced or metastatic disease):</i>
<b>IV:</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and nivolumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34102137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34102137'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLOT regimen (locally advanced, recurrent, or metastatic disease</i>
<i>)</i>: <b>IV: </b>85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and docetaxel) for up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18669868']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18669868'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dose optimization for advanced, palliative treatment in frail and/or elderly patients: </i>A dose optimization study that examined 60%, 80%, or 100% of a 130 mg/m<sup>2</sup> dose once every 21 days (in combination with capecitabine) found that the 60% dose was not inferior (for progression-free survival) and had less toxicity compared to the full dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hall.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hall.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment of advanced or metastatic disease:</i> Treatment with doublet, rather than triplet, chemotherapy is preferred in the palliative setting due to increased toxicity (without clear benefit) with triplet regimens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32861308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32861308'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d79fad62-a2e8-47a1-8d65-a54bda65c2f8">Neuroendocrine tumors: GI/carcinoid, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroendocrine tumors: GI/carcinoid, refractory (off-label use):</b>
<b>IV:</b> 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16937105']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16937105'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24894929-2b6f-4f03-9c28-dac7cd8e83c1">Non-Hodgkin lymphomas, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas, relapsed/refractory (off-label use): IV:</b> 100 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with gemcitabine and rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18005385','lexi-content-ref-17990179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18005385','lexi-content-ref-17990179'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8ca88c47-fed2-4025-88d5-3331e749f45f">Ovarian cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian cancer, advanced (off-label use): IV:</b> 130 mg/m<sup>2</sup> once every 3 weeks (as a single agent) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11886003','lexi-content-ref-10715288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11886003','lexi-content-ref-10715288'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2ef5d06-eb08-4064-9765-eeb1fa388d2e">Pancreatic cancer, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, advanced or metastatic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFIRINOX regimen: </i>
<b>IV:</b> 85 mg/m<sup>2</sup> every 2 weeks (in combination with fluorouracil, leucovorin, and irinotecan) for up to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21561347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21561347'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOX regimen (second-line therapy):</i>
<b>IV:</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil and leucovorin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19826418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19826418'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>OFF regimen (second-line therapy):</i>
<b>IV:</b> 85 mg/m<sup>2</sup> on days 8 and 22 every 6 weeks (in combination with fluorouracil and leucovorin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982456','lexi-content-ref-21565490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982456','lexi-content-ref-21565490'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CAPOX regimen: </i>
<b>IV:</b> 110 to 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18756532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18756532'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a39e464-8bb6-4795-a1b3-a3b1646f0ac0">Pancreatic cancer, potentially curable, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, potentially curable, adjuvant therapy (off-label use): Note:</b> American Society of Clinical Oncology (ASCO) guidelines recommend 6 months of adjuvant therapy if recovery is complete; if preoperative chemotherapy therapy was received, a total of 6 months of adjuvant therapy (including the preoperative regimen) is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31180816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31180816'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>mFOLFIRINOX regimen: </i>
<b>IV:</b> 85 mg/m<sup>2</sup> every 2 weeks (in combination with fluorouracil, leucovorin, and irinotecan; modified FOLFIRINOX regimen) for 24 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30575490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30575490'])">Ref</a></span>). According to ASCO guidelines, mFOLFIRINOX is the preferred first-line adjuvant regimen for potentially curable disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31180816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31180816'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="80e1258c-674d-41d4-a1b2-d3be69bcf8cf">Small bowel adenocarcinoma, advanced unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small bowel adenocarcinoma, advanced unresectable or metastatic (off-label use): Note:</b> Ampullary adenocarcinomas were excluded from some studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28536826','lexi-content-ref-22481063','lexi-content-ref-20223786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28536826','lexi-content-ref-22481063','lexi-content-ref-20223786'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CAPOX regimen:</i>
<b>IV:</b> 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with capecitabine) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19164203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19164203'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>mFOLFOX or FOLFOX regimen:</i>
<b>IV:</b> 85 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil and leucovorin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28536826','lexi-content-ref-22481063','lexi-content-ref-20223786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28536826','lexi-content-ref-22481063','lexi-content-ref-20223786'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="474f7a05-9f1d-4b18-ba1f-8d93ff3193a6">Testicular cancer, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Testicular cancer, refractory (off-label use):</b>
<b>IV:</b> 130 mg/m<sup>2</sup> every 3 weeks in combination with gemcitabine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16757095','lexi-content-ref-14701772','lexi-content-ref-14998855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16757095','lexi-content-ref-14701772','lexi-content-ref-14998855'])">Ref</a></span>) <b>or</b> 130 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with gemcitabine and paclitaxel) for up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18006893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18006893'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89d34419-0cf2-42aa-8803-e035ccd62391">Unknown primary cancer, recurrent or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Unknown primary cancer, recurrent or refractory (off-label use):</b>
<b>IV:</b> 130 mg/m<sup>2</sup> on day 1 of a 21-day cycle (in combination with capecitabine) for 6 cycles or may continue until clinical benefit no longer realized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20209610']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20209610'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990682"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS; Kenar D. Jhaveri , MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> CrCl may be calculated using the Cockroft-Gault equation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10663631','lexi-content-ref-12860942','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10663631','lexi-content-ref-12860942','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl 20 to &lt;30 mL/minute: Administer 75% to 100% of the usual indication-specific dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>). For example, the manufacturer’s labeling suggests reducing the dose from 85 to 65 mg/m<sup>2</sup> in patients with colorectal cancer. Alternatively, the increased exposure to oxaliplatin has not been associated with increased drug-related toxicity in patients with CrCl <span style="text-decoration: underline">&gt;</span>20 mL/minute; therefore, administration of 100% of the usual indication-specific dose may also be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12860942']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12860942'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;20 mL/minute: Administer 75% of the usual indication-specific dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>). For example, the manufacturer's labeling suggests reducing the dose from 85 to 65 mg/m<sup>2</sup> in patients with colorectal cancer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Partially dialyzable (56% of free platinum (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29578402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29578402'])">Ref</a></span>)):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>Avoid use when possible due to limited data. Multiple case reports have described various dosing and timing strategies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26846320','lexi-content-ref-25314931','lexi-content-ref-29578402','lexi-content-ref-21499694','lexi-content-ref-21892270','lexi-content-ref-32066346','lexi-content-ref-Nagatani.1','lexi-content-ref-Osawa.1','lexi-content-ref-31243213','lexi-content-ref-29315736','lexi-content-ref-31689749','lexi-content-ref-20085906']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26846320','lexi-content-ref-25314931','lexi-content-ref-29578402','lexi-content-ref-21499694','lexi-content-ref-21892270','lexi-content-ref-32066346','lexi-content-ref-Nagatani.1','lexi-content-ref-Osawa.1','lexi-content-ref-31243213','lexi-content-ref-29315736','lexi-content-ref-31689749','lexi-content-ref-20085906'])">Ref</a></span>). If necessary, a reasonable approach would be to begin with 75% of the usual recommended dose and make subsequent adjustments based on efficacy and toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Can consider dialyzing after the infusion to decrease risk of toxicity; allow the infusion to be completed at least 1.5 to 2 hours before dialysis to allow for oxaliplatin to distribute into the tissue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29578402','lexi-content-ref-32066346','lexi-content-ref-Nagatani.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29578402','lexi-content-ref-32066346','lexi-content-ref-Nagatani.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Dialyzability unknown:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Avoid use when possible due to lack of data (has not been studied). If necessary, dose as for patients with CrCl &lt;20 mL/minute. If patient has significant residual kidney function, then dosing should be individualized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Appropriate dosing requires consideration of adequate drug concentrations. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> There are no data available in patients on CRRT (has not been studied). If necessary, administer 100% of the usual indication-specific dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Appropriate dosing requires consideration of adequate drug concentrations. Close monitoring of response and adverse reactions (eg, neurotoxicity) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> There are no data available in patients on PIRRT (has not been studied). If necessary, administer 100% of the usual indication-specific dose. Can consider dialyzing after the infusion to decrease risk of toxicity; allow the infusion to be completed at least 1.5 to 2 hours before dialysis to allow for oxaliplatin to distribute into the tissue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987984"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatic impairment prior to treatment initiation</i>
<i>: </i></p>
<p style="text-indent:-2em;margin-left:4em;">Mild, moderate, or severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14523790','lexi-content-ref-17575231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14523790','lexi-content-ref-17575231'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Hepatotoxicity during treatment:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Portal hypertension or increased LFTs that cannot be explained by liver metastases: Consider evaluating for hepatic vascular disorders.</p></div>
<div class="block doo drugH1Div" id="F20342799"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">
<i>American Society of Clinical Oncology guidelines for appropriate systemic therapy dosing in adults with cancer with a BMI ≥30 kg/m<sup>2</sup>: </i>Utilize patient's actual body weight for calculation of BSA- or weight-based dosing; manage regimen-related toxicities in the same manner as for patients with a BMI &lt;30 kg/m<sup>2</sup>; if a dose reduction is utilized due to toxicity, may consider resumption of full, weight-based dosing (or previously tolerated dose level) with subsequent cycles only if dose escalations are allowed in the prescribing information, if contributing underlying factors (eg, hepatic or kidney impairment) are sufficiently resolved, AND if performance status has markedly improved or is considered adequate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33939491']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33939491'])">Ref</a></span>).</p></div>
<div class="block dot drugH1Div" id="F204286"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose reduction recommendations in the following tables are considered applicable to patients with CrCl ≥30 mL/minute. For patients with CrCl &lt;30 mL/minute or on renal replacement therapy, further dose reductions may be necessary for patients experiencing oxaliplatin-associated toxicities; dose should be individualized.</p>
<table border="1" frame="border" rules="all">
<caption>
<b>Oxaliplatin Dosage Adjustment for Adjuvant Therapy in Stage III Colon Cancer</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;">Oxaliplatin dose modification</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>a</sup> Avoid mucositis prophylaxis with ice chips, exposure to cold temperatures, or consumption of cold food/beverages during or within hours after oxaliplatin infusion (may exacerbate symptoms).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">GI toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Grades 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">After recovery, reduce oxaliplatin dose to 75 mg/m<sup>2</sup> (also reduce fluorouracil doses).</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Hematologic toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 4 neutropenia or neutropenic fever</p></td>
<td align="center">
<p style="text-indent:0em;">Delay next dose until neutrophils recover to ≥1,500/mm<sup>3</sup>, then reduce oxaliplatin dose to 75 mg/m<sup>2</sup>.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4 thrombocytopenia</p></td>
<td align="center">
<p style="text-indent:0em;">Delay next dose until platelets recover to ≥75,000/mm<sup>3</sup>, then reduce oxaliplatin dose to 75 mg/m<sup>2</sup>.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Peripheral sensory neuropathy<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Persistent grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Consider reducing oxaliplatin dose to 75 mg/m<sup>2</sup>.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Persistent grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Consider discontinuing oxaliplatin.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue oxaliplatin.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption>
<b>Oxaliplatin Dosage Adjustment for Advanced Colorectal Cancer</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;">Severity</p></th>
<th align="center">
<p style="text-indent:0em;">Oxaliplatin dose modification</p></th></tr></thead>
<tfoot>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>a</sup> Avoid mucositis prophylaxis with ice chips, exposure to cold temperatures, or consumption of cold food/beverages during or within hours after oxaliplatin infusion (may exacerbate symptoms).</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">GI toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Grades 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;">After recovery, reduce oxaliplatin dose to 65 mg/m<sup>2</sup> (also reduce fluorouracil doses).</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Hematologic toxicity</p></td>
<td align="center">
<p style="text-indent:0em;">Grade 4 neutropenia or neutropenic fever</p></td>
<td align="center">
<p style="text-indent:0em;">Delay next dose until neutrophils recover to ≥1,500/mm<sup>3</sup>, then reduce oxaliplatin dose to 65 mg/m<sup>2</sup>.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 3 or 4 thrombocytopenia</p></td>
<td align="center">
<p style="text-indent:0em;">Delay next dose until platelets recover to ≥75,000/mm<sup>3</sup>, then reduce oxaliplatin dose to 65 mg/m<sup>2</sup>.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Neuropathy<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;">Persistent grade 2</p></td>
<td align="center">
<p style="text-indent:0em;">Consider reducing oxaliplatin dose to 65 mg/m<sup>2</sup>.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Persistent grade 3</p></td>
<td align="center">
<p style="text-indent:0em;">Consider discontinuing oxaliplatin.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Grade 4</p></td>
<td align="center">
<p style="text-indent:0em;">Discontinue oxaliplatin.</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption>
<b>Oxaliplatin Dosage Adjustment for Adjuvant Therapy in Stage III Colon Cancer AND for Advanced Colorectal Cancer</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">Adverse reaction</p></th>
<th align="center">
<p style="text-indent:0em;">Oxaliplatin dose modification</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Acute toxicities (including non–life-threatening infusion reaction)</p></td>
<td align="center">
<p style="text-indent:0em;">Longer infusion time (increasing infusion duration from 2 hours to 6 hours) may mitigate acute toxicities.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Hypersensitivity</p></td>
<td align="center">
<p style="text-indent:0em;">Immediately and permanently discontinue oxaliplatin (and administer appropriate management for hypersensitivity).</p>
<p style="text-indent:0em;">Oxygen and bronchodilators have also been used for hypersensitivity management (Kim 2009).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Immune-mediated thrombocytopenia</p></td>
<td align="center">
<p style="text-indent:0em;">Consider discontinuing oxaliplatin.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Posterior reversible encephalopathy syndrome</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue oxaliplatin.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Pulmonary symptoms (unexplained pulmonary symptoms such as crackles, dyspnea, nonproductive cough, pulmonary infiltrates)</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold oxaliplatin until interstitial lung disease or pulmonary fibrosis are excluded.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Pulmonary toxicity (confirmed interstitial lung disease or pulmonary fibrosis)</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue oxaliplatin.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Rhabdomyolysis (signs or symptoms)</p></td>
<td align="center">
<p style="text-indent:0em;">Permanently discontinue oxaliplatin.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Sepsis or septic shock</p></td>
<td align="center">
<p style="text-indent:0em;">Withhold oxaliplatin treatment.</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F204264"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary. Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F50906907"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13031" href="/d/html/13031.html" rel="external">see "Oxaliplatin: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">Refer to individual protocols; details concerning dosing in combination regimens should also be consulted. Oxaliplatin is associated with moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7177d86f-32ee-49d7-9ed7-ee88e7f0a1c0">Solid tumors, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumors, relapsed/refractory:</b> Limited data available; several regimens reported; efficacy results highly variable; has shown limited activity in pediatric patients (primarily some delayed tumor progression reported) and an acceptable safety profile; should not be used first-line; reserved for refractory cases; patients should be hydrated prior to and during administration (eg, 3 L/m<sup>2</sup>/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21572345','lexi-content-ref-24942022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21572345','lexi-content-ref-24942022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lam 2015; McGregor 2009:</i> Children and Adolescents: IV: 130 mg/m<sup>2</sup> over 2 hours on day 1 in combination with etoposide with/without ifosfamide every 21 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Geoerger 2011; Macy 2013: </i>Children and Adolescents: IV: 100 mg/m<sup>2</sup> over 2 hours on day 1 of a 14-day cycle in combination with gemcitabine or fluorouracil/leucovorin.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hartmann 2011:</i> Children and Adolescents: IV: 85 mg/m<sup>2</sup> over 2 hours on day 1 in combination with irinotecan (day 1) and gemcitabine (day 1 and 8).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6fc7672-3ba1-4f98-9c9e-f6cd53c46ea2">Neuroblastoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma, </b>
<b>relapsed</b>
<b> or </b>
<b>refractory: </b>Limited data available; efficacy results highly variable; should not be used first-line; reserved for refractory case. Children ≥2 years and Adolescents: IV: 105 mg/m<sup>2</sup> on day 1 in combination with doxorubicin on a 21-day cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23335436','lexi-content-ref-25551355']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23335436','lexi-content-ref-25551355'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustments for toxicity:</b> The presented dosing adjustments are based on experience in adult patients. Refer to specific protocol management in pediatric patients if available.</p>
<p style="text-indent:-2em;margin-left:4em;">Adult:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Acute toxicities:</i> Longer infusion time (6 hours) may mitigate acute toxicities (eg, pharyngolaryngeal dysesthesia).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Neurosensory events:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Persistent (&gt;7 days) grade 2 neurosensory events:</p>
<p style="text-indent:-2em;margin-left:10em;">Adjuvant treatment of stage III colon cancer: Reduce dose to 75 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:10em;">Advanced colorectal cancer: Reduce dose to 65 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:8em;">Consider withholding oxaliplatin for grade 2 neuropathy lasting &gt;7 days despite dose reduction.</p>
<p style="text-indent:-2em;margin-left:8em;">Persistent (&gt;7 days) grade 3 neurosensory events: Consider discontinuing oxaliplatin.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Gastrointestinal toxicity (grade 3/4) occurring despite prophylactic treatment:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Adjuvant treatment of stage III colon cancer: Delay next dose until recovery from toxicity, then reduce dose to 75 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:8em;">Advanced colorectal cancer: Delay next dose until recovery from toxicity, then reduce dose to 65 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Hematologic toxicity (grade 4 neutropenia, febrile neutropenia, or grade 3/4 thrombocytopenia):</i></p>
<p style="text-indent:-2em;margin-left:8em;">Adjuvant treatment of stage III colon cancer: Delay next dose until neutrophils recover to ≥1,500/mm<sup>3</sup> and platelets recover to ≥75,000/mm<sup>3</sup>, then reduce dose to 75 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:8em;">Advanced colorectal cancer: Delay next dose until neutrophils recover to ≥1,500/mm<sup>3</sup> and platelets recover to ≥75,000/mm<sup>3</sup>, then reduce dose to 65 mg/m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Pulmonary toxicity (unexplained respiratory symptoms, including nonproductive cough, dyspnea, crackles, pulmonary infiltrates):</i> Discontinue until interstitial lung disease or pulmonary fibrosis have been excluded.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Rhabdomyolysis:</i> Discontinue for signs/symptoms of rhabdomyolysis.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Sepsis or septic shock:</i> Withhold treatment.</p></div>
<div class="block dorp drugH1Div" id="F51151043"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; refer to individual protocols; based on experience in adult patients, dosing adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51151044"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric specific recommendations; refer to individual protocols; based on experience in adult patients, some have suggested that dosage adjustment is not necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14523790','lexi-content-ref-17575231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14523790','lexi-content-ref-17575231'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F204234"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Percentages reported with monotherapy.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (31%), anorexia (20%), constipation (31%), diarrhea (46%; grades 3/4: 4%), nausea (64%; grades 3/4: 4%), stomatitis (2% to 14%), vomiting (37%; grades 3/4: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (64%; grades 3/4: 1%), leukopenia (13%), thrombocytopenia (30%; grades 3/4: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (36%), increased serum alkaline phosphatase (42%), increased serum aspartate aminotransferase (54%), increased serum bilirubin (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (61%), headache (13%), insomnia (11%), pain (14%), peripheral neuropathy (76%, grades 3/4: 7%; acute: 65%, grades 3/4: 5%; delayed [persistent]: 43%, grades 3/4: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (11%), dyspnea (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (25%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (5%), edema (10%), flushing (3%), peripheral edema (5%), thromboembolism (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (3%), palmar-plantar erythrodysesthesia (1%), skin rash (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Dehydration (5%), hypokalemia (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (5%), dyspepsia (7%), flatulence (3%), gastroesophageal reflux disease (1%), hiccups (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Dysuria (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (3%; including anaphylaxis, nonimmune anaphylaxis)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (9%, including erythema at injection site, pain at injection site, swelling at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (7%), rigors (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Abnormal lacrimation (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (5% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (2%), pharyngitis (2%), pharyngolaryngeal dysesthesia (grades 3/4: 1% to 2%), rhinitis (6%), upper respiratory tract infection (7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Reversible posterior leukoencephalopathy syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pulmonary fibrosis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysphagia, gastrointestinal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, prolonged QT interval on ECG (Hancox 2016), septic shock, torsades de pointes (Hancox 2016), ventricular arrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Lactic acidosis (Smith 2019), metabolic acidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis (including <i>Clostridioides difficile</i>-associated diarrhea), esophagitis, intestinal obstruction, pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia (immuno-allergic; including Evan syndrome [Earle 2001]), hemolytic-uremic syndrome (Saad 2022), immune thrombocytopenia (Woo 2015), leukemia (Carneiro 2006), thrombotic microangiopathy (Saad 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic fibrosis (Kang 2013), hepatic focal nodular hyperplasia, hepatic sinusoidal obstruction syndrome (veno-occlusive disease of liver) (Seo 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, angioedema, hypersensitivity angiitis (Quack 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Neutropenic sepsis, sepsis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cranial nerve palsy, decreased deep tendon reflex, dysarthria, Lhermitte sign (Okamoto 2020), seizure</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Fasciculations, laryngospasm, rhabdomyolysis (Pissarra 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Decreased visual acuity (Mesquida 2010), optic neuritis, temporary vision loss (Ah-Thiane 2021), visual field loss (Mesquida 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Deafness, hearing loss (can be irreversible) (Kim 2020; Oh 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Yamada 2019), acute kidney injury (Yamada 2019), renal tubular necrosis (Jain 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial lung disease (including exacerbation of preexisting interstitial lung disease) (Ryu 2011; Wilcox 2008), pneumonia (including interstitial pneumonia [Taooka 2021])</p></div>
<div class="block coi drugH1Div" id="F204247"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to oxaliplatin, other platinum-containing compounds, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Preexisting peripheral sensitive neuropathy with functional impairment; pregnancy; breastfeeding; severe renal impairment (CrCl &lt;30 mL/minute).</p></div>
<div class="block war drugH1Div" id="F204232"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone marrow suppression: Grade 3 and 4 neutropenia occurs commonly with oxaliplatin in combination with fluorouracil and leucovorin; sepsis, neutropenic sepsis, and septic shock have been reported with oxaliplatin (some fatal). Grade 3 and 4 thrombocytopenia has also occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiotoxicity: QT prolongation and ventricular arrhythmias, including fatal torsades de pointes, have been reported with oxaliplatin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Oxaliplatin is an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemorrhage: GI bleeding, hematuria, and epistaxis have been reported with oxaliplatin; there have been case reports of death due to intracerebral hemorrhage. Prolonged PT and INR occasionally associated with hemorrhage have been reported in patients also receiving anticoagulants while on oxaliplatin. Thrombocytopenia and immune-mediated thrombocytopenia have been observed with oxaliplatin; immune-mediated thrombocytopenia has been associated with a rapid thrombocytopenia onset along with a greater risk of bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Elevated transaminases and alkaline phosphatase have occurred with oxaliplatin. Liver biopsy has revealed peliosis, nodular regenerative hyperplasia or sinusoidal alterations, perisinusoidal fibrosis, and veno-occlusive lesions. Consider evaluating for hepatic vascular disorders in patients who develop portal hypertension or increased LFTs that cannot be explained by liver metastases.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious and fatal hypersensitivity reactions (including anaphylaxis) may occur within minutes of oxaliplatin administration and during any cycle. Grade 3 or 4 hypersensitivity has been observed (rare). Allergic reactions are similar to reactions reported with other platinum analogs and may occur with any cycle. Reactions typically occur after multiple cycles; in retrospective reviews, reaction occurred at a median of 7 to 9 cycles, with an onset of 5 to 70 minutes (Kim 2009; Polyzos 2009). Symptoms may include bronchospasm (rare), erythema, hypotension (rare), pruritus, rash, and/or urticaria; previously untreated patients have also experienced flushing, diaphoresis, diarrhea, shortness of breath, chest pain, hypotension, syncope, and disorientation. According to the manufacturer, rechallenge is contraindicated (deaths due to anaphylaxis have been associated with platinum derivatives). In patients rechallenged after mild hypersensitivity, reaction recurred at a higher level of severity; for patients with severe hypersensitivity, rechallenge (with 2 to 3 days of antihistamine and corticosteroid premedication, and prolongation of infusion time) allowed for 2 to 4 additional oxaliplatin cycles; however, rechallenge was not feasible in nearly two-thirds of patients due to the severity of the initial reaction (Polyzos 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuropathy: Two types of peripheral sensory neuropathy may occur: The first type of neuropathy is an acute presentation (within hours to 2 days), reversible (resolves within 14 days), with primarily peripheral symptoms that are often exacerbated by cold. Symptoms may include transient paresthesia, dysesthesia, and hypoesthesia in the hands, feet, perioral area, or throat; jaw spasm, abnormal tongue sensation, pharyngolaryngeal dysesthesia, dysarthria, eye pain, and a feeling of chest pressure have also been observed. Avoid mucositis prophylaxis with ice chips, exposure to cold temperatures, or consumption of cold food/beverages during or within hours after oxaliplatin infusion (may exacerbate symptoms). Acute neuropathy commonly recurs with subsequent doses. Cold-triggered neuropathy may last up to 7 days after oxaliplatin administration (Grothey 2011). The second type of neuropathy is a more persistent (&gt;14 days) presentation that usually is characterized by paresthesia, dysesthesias, and hypoesthesias and may interfere with daily activities (eg, writing, buttoning, swallowing, difficulty walking). These symptoms may improve in some patients upon discontinuing treatment. In a retrospective evaluation of patients treated with oxaliplatin for colorectal cancer, the incidence of peripheral sensory neuropathy was similar between diabetic and nondiabetic patients (Ramanathan 2010). Several retrospective studies (as well as a small, underpowered randomized trial) have suggested calcium and magnesium infusions before and after oxaliplatin administration may reduce incidence of cumulative sensory neuropathy; however, a randomized, placebo-controlled, double-blind study in patients with colorectal cancer suggests there is no benefit of calcium and magnesium in preventing sensory neuropathy or in decreasing oxaliplatin discontinuation rates (Loprinzi 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Posterior reversible encephalopathy syndrome: Cases of posterior reversible encephalopathy syndrome have been reported (rare). Signs/symptoms include headache, mental status changes, seizure, blurred vision, blindness, and/or other vision changes; may be associated with hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Oxaliplatin is associated with pulmonary fibrosis (rare), which may be fatal. Pulmonary toxicity may present with dyspnea, cough, and/or hypoxia; grade 3 and 4 events have occurred. Eosinophilic pneumonia has been reported rarely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rhabdomyolysis: Rhabdomyolysis (including fatal cases) has been reported with oxaliplatin.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Patients ≥65 years of age experienced a higher incidence of diarrhea and grade 3 or 4 neutropenia and may be more susceptible to dehydration, hypokalemia, leukopenia, fatigue, and syncope.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: Oxaliplatin is for IV administration. Administration via the intraperitoneal route (not an approved administration route) is associated with peritoneal hemorrhage and hemorrhagic complications (Charrier 2016).</p></div>
<div class="block foc drugH1Div" id="F204242"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/10 mL (10 mL); 100 mg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/10 mL (10 mL); 100 mg/20 mL (20 mL); 200 mg/40 mL (40 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea); 100 mg (1 ea)</p></div>
<div class="block geq drugH1Div" id="F204229"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323568"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Oxaliplatin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/10 mL (per mL): $0.86 - $21.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/20 mL (per mL): $0.74 - $21.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/40 mL (per mL): $6.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Oxaliplatin Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $120.00 - $1,162.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $240.00 - $2,325.15</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867777"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (10 mL, 20 mL, 30 mL, 40 mL)</p></div>
<div class="block adm drugH1Div" id="F204244"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer as IV infusion over 2 hours; extend infusion time to 6 hours for acute toxicities.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label rate:</i> A fixed infusion rate of 1 mg/m<sup>2</sup>/minute (eg, an 85 mg/m<sup>2</sup> dose infused over 85 minutes) has been used and did not show a statistically significant difference in the rate of hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27072569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27072569'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Flush infusion line with D<sub>5</sub>W prior to administration of any concomitant medication. Avoid mucositis prophylaxis with ice chips, exposure to cold temperatures, or consumption of cold food/beverages during or within hours after oxaliplatin infusion (may exacerbate acute neurological symptoms). Do not use needles or administration sets containing aluminum. When used in combination with a fluoropyrimidine (eg, 5-FU), infuse oxaliplatin first.</p>
<p style="text-indent:0em;margin-top:2em;">Oxaliplatin is associated with a moderate emetic potential and is known to cause delayed nausea and vomiting; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-top:2em;">Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation; monitor IV site for redness, swelling, or pain.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p>
<p style="text-indent:0em;margin-left:2em;">Information conflicts regarding use of warm or cold compresses. Cold compresses may cause local vasoconstriction and reduce cellular injury; however, may cause or exacerbate peripheral neuropathy; warm compresses may increase local drug removal, although may also increase cellular uptake and injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16595069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16595069'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-left:2em;">Extravasation of moderate to large oxaliplatin doses (&gt;40 mg) can result in pronounced tissue inflammation resembling erysipelas. Anti-inflammatory medication, such as high-dose oral dexamethasone, may reduce the severity of the inflammatory reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14581435']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14581435'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52613485"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oxaliplatin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer as IV infusion over 2 to 6 hours. Flush infusion line with D5W prior to and following administration of oxaliplatin. Do <b>not</b> use IV administration sets containing aluminum. When used in combination with a fluoropyrimidine (eg, 5-FU), infuse oxaliplatin first.</p>
<p style="text-indent:-2em;margin-left:2em;">Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation; monitor IV site for redness, swelling, or pain. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Information conflicts regarding use of warm or cold compresses. Cold compresses could potentially precipitate or exacerbate peripheral neuropathy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16595069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16595069'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132766"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and &lt;USP 800&gt; recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block use drugH1Div" id="F204243"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Colon cancer, stage III (adjuvant therapy):</b> Adjuvant treatment of stage III colon cancer (in combination with infusional fluorouracil and leucovorin) after complete resection of primary tumor.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer, advanced:</b> Treatment of advanced colorectal cancer (in combination with infusional fluorouracil and leucovorin).</p></div>
<div class="block off-label drugH1Div" id="F25469518"><span class="drugH1">Use: Off-Label: Adult</span><p>Biliary tract cancer, advanced; Chronic lymphocytic leukemia, refractory; Esophageal cancer; Gastric cancer; Neuroendocrine tumors: GI/carcinoid, refractory; Non-Hodgkin lymphomas, relapsed/refractory; Ovarian cancer, advanced; Pancreatic cancer, advanced or metastatic; Pancreatic cancer, potentially curable, adjuvant therapy; Small bowel adenocarcinoma, advanced or metastatic; Testicular cancer, refractory; Unknown primary cancer, recurrent or refractory</p></div>
<div class="block mst drugH1Div" id="F204295"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Oxaliplatin may be confused with Aloxi, carboplatin, cisplatin</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299798"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OCT2</p></div>
<div class="block dri drugH1Div" id="F204236"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capecitabine: Oxaliplatin may enhance the nephrotoxic effect of Capecitabine. Oxaliplatin may enhance the neurotoxic (peripheral) effect of Capecitabine. Oxaliplatin may enhance the QTc-prolonging effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Platinum Derivatives may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Levoketoconazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taxane Derivatives: Platinum Derivatives may enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.  Management: Administer paclitaxel before cisplatin, when given as sequential infusions, to limit toxicity. Problems associated with other taxane/platinum combinations are possible, although unsubstantiated. Administering the taxane before platinum is likely warranted<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topotecan: Platinum Derivatives may enhance the adverse/toxic effect of Topotecan.  Management: Consider administering platinum derivatives after topotecan when possible to minimize toxicity or using lower doses if administering platinum derivatives prior to topotecan. Monitor for hematologic toxicity (eg, neutropenia, thrombocytopenia).<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308590"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Verify pregnancy status prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment and for at least 9 months after the last oxaliplatin dose. Patients with partners who can become pregnant should use effective contraception during treatment and for 6 months after the last oxaliplatin dose.</p>
<p style="text-indent:0em;margin-top:2em;">Oxaliplatin may adversely affect female fertility and have an intermediate risk of treatment-related azoospermia and male infertility (ESMO [Lambertini 2020]; Levi 2015). Recommendations are available for fertility preservation of male and female patients to be treated with anticancer agents (ASCO [Oktay 2018]; Klipstein 2020).</p></div>
<div class="block pri drugH1Div" id="F204249"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to oxaliplatin may cause fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following maternal use of oxaliplatin during pregnancy are available (Frydenberg 2020; Kozai 2022; NTP 2013; Petruzzelli 2020).</p>
<p style="text-indent:0em;margin-top:2em;">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team) approach. In general, if chemotherapy is indicated, it should be avoided in the first trimester, there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (877-635-4499).</p></div>
<div class="block brc drugH1Div" id="F3017308"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Oxaliplatin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of oxaliplatin in breast milk are available from a lactating patient treated for colorectal cancer 7 months postpartum. Oxaliplatin 200 mg was infused every 3 weeks for 4 doses. The patient continued to express breast milk, but infant feeds were replaced with formula. Breast milk was sampled 34 and 65 days following the last oxaliplatin dose; platinum breast concentrations were 7.8 ng/mL and 10.3 ng/mL, respectively. The breast milk supply significantly decreased over time during chemotherapy and radiation treatments (Krutsch 2023).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends discontinuing breastfeeding during oxaliplatin treatment and for 3 months after the last oxaliplatin dose.</p></div>
<div class="block mop drugH1Div" id="F204240"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">CBC with differential, blood chemistries, including serum creatinine, ALT, AST, and bilirubin (baseline, prior to each cycle, and as clinically indicated), electrolytes, including potassium and magnesium (prior to and periodically during treatment); INR and PT (in patients on oral anticoagulant therapy; increase the frequency of monitoring in patients who receive oxaliplatin and oral anticoagulants). Evaluate pregnancy status prior to treatment initiation in females of reproductive potential. ECG monitoring is recommended in patients at risk for QT prolongation, heart failure, bradyarrhythmias, and electrolyte abnormalities and in patients taking concomitant medications known to cause QT prolongation (including class Ia and III antiarrhythmics). Perform neurologic evaluation prior to each dose and periodically thereafter. Monitor for signs/symptoms of hypersensitivity, pulmonary toxicity, posterior reversible encephalopathy syndrome (diagnosis is confirmed with MRI), neuropathy, bleeding, and GI toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p></div>
<div class="block pha drugH1Div" id="F204231"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Oxaliplatin, a platinum derivative, is an alkylating agent. Following intracellular hydrolysis, the platinum compound binds to DNA forming cross-links which inhibit DNA replication and transcription, resulting in cell death. Cytotoxicity is cell-cycle nonspecific.</p></div>
<div class="block phk drugH1Div" id="F204246"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 440 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;90% primarily albumin and gamma globulin (irreversible binding to platinum).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Nonenzymatic (rapid and extensive), forms active and inactive derivatives.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: Oxaliplatin ultrafilterable platinum (terminal): Median: 293 hours; range: 187 to 662 hours (Beaty 2010).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Oxaliplatin ultrafilterable platinum: Distribution: Alpha phase: 0.43 hours; Beta phase: 16.8 hours; Terminal: 392 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~54%); feces (~2%).</p></div>
<div class="block phksp drugH1Div" id="F51160060"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: The mean AUC of unbound platinum increases as renal function decreases: 40% increase with mild (CrCl 50 to 80 mL/minute), 95% increase with moderate (CrCl 30 to 49 mL/minute), and 342% increase with severe (CrCl &lt;30 mL/minute) renal impairment compared with patients with normal renal function. The mean C<sub>max</sub> was 38% higher in patients with severe impairment compared with patients with normal renal function.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F5539908"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin ebewe | Oxaliplatin Mylan | Oxitan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Crisapla | Dabenzol | Dacplat | Fada oxaliplatino | Goxyral | Mitog | O plat | Oliptino | Oxalinova | Oxaliplatino argenmex | Oxaliplatino delta farma | Oxaliplatino gp pharm | Oxaliplatino kemex | Oxaliplatino servycal | Oxaltie | Uxalun | Xaliplat</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin accord | Oxaliplatin Arcana | Oxaliplatin hospira | Oxaliplatin kabi | Oxaliplatin mayne | Oxaliplatin medac | Oxaliplatin stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">As Oxaliplatin | DBL Oxaliplatin | Eloxatin | Oxalatin | Oxaliccord | Oxaliplatin accord | Oxaliplatin actavis | Oxaliplatin kabi | Oxaliplatin link | Oxaliplatin myx | Oxaliplatin sun | Oxaliplatin sz | Xalox</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin actavis | Oxaliplatine | Oxaliplatine Ebewe | Oxaliplatine EG | Oxaliplatine Fresenius Kabi | Oxaliplatine sandoz</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin accord | Oxaliplatin actavis | Oxaliplatin bulgermed | Oxaliplatine | Xatinel</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bioezulen | Collectro | Dosaplatin | Eloxatin | Ezulen | O plat | Oxa | Oxalibbs | Oxalimeiz | Oxaliplatina | Tevaoxali | Uxalun</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Eloxatine | Eloxatine lyophilisat | Oxaliplatin accord | Oxaliplatin actavis | Oxaliplatin Eco | Oxaliplatin fresenius | Oxaliplatin medac | Oxaliplatin teva | Oxaliplatin Zentiva</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Oliplat</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Crisapla | Eloxatin | Hoxalira | O plat | Oxaliplatino</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai heng | Ai ke bo kang | Ao Bo | Ao zheng nan | Cao bo | Eloxatin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Al oxa | Crisapla | Eloxatin | Entia | Goxyral | Hoxalira | O plat | Oxaliplatino | Oxaliplatino sandoz | Oxalipro | Oxaliseven | Oxerin | Oxplar | Xaliplat | Zolaxat</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin accord | Oxaliplatin actavis | Oxaliplatin hospira | Oxaliplatin kabi | Oxaliplatin pharmagen | Oxaliplatin ratiopharm | Oxaliplatin stada | Oxaliplatin winthrop | Oxaliplatina medac | Oxaliplatinum Medac | Oxaliquid | Rezidol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Axioplatin | Axiplatin | Bendaplatin | Croloxat | Eloxatin | Euroxaliplatin | Medoxa | Oxaliplan | Oxaliplatin accord | Oxaliplatin actavis | Oxaliplatin aqvida | Oxaliplatin aurobindo | Oxaliplatin Bendalis | Oxaliplatin beta | Oxaliplatin bhardwaj | Oxaliplatin gry | Oxaliplatin Haemato pharm | Oxaliplatin Hexal | Oxaliplatin kabi | Oxaliplatin Lapharm | Oxaliplatin nc | Oxaliplatin omnicare | Oxaliplatin Onkovis | Oxaliplatin orcazwei | Oxaliplatin Profusio | Oxaliplatin Resolute | Oxaliplatin ribosepharm | Oxaliplatin sandoz | Oxaliplatin stada | Oxaliplatin sun | Oxaliplatin Tillomed | Oxaliplatin Vipharm | Oxaliplatin vitane | Oxaliplatin winthrop | Oxaliquid | Oxalisachs | Riboxatin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Eloxatine | Omiplax | Oxitan</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Crisapla | Dabenzol | Eloxatin | O plat | Oxaliplatino | Oxaltie</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin accord | Oxaliplatin actavis | Oxaliplatin hospira | Oxaliplatin kabi | Oxaliplatin teva</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Oxaliplatin actavis | Oxaliplatin ebewe | Oxaplatin | Oxitan</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatino Accord | Oxaliplatino Actavis | Oxaliplatino gp pharm | Oxaliplatino Kabi | Oxaliplatino Mylan | Oxaliplatino qilu | Oxaliplatino Ratiopharm | Oxaliplatino sandoz | Oxaliplatino Stada | Oxaliplatino sun | Oxaliplatino Teva</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Neoxal | Oxaliplatin sandoz | Xalipat</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin accord | Oxaliplatin medac | Oxaliplatin Mylan | Oxaliplatin teva</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Eloxatine | Oxaliplatin winthrop | Oxaliplatine accord | Oxaliplatine Ebewe | Oxaliplatine Hospira | Oxaliplatine kabi | Oxaliplatine Medac | Oxaliplatine Ratiopharm</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin accord | Oxaliplatin medac</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Eloxatine | Oxaliplatin medicus | Oxaliplatin teva | Oxaliplatin/deltapharma | Oxaliplatin/hospira | Oxaliplatin/medac | Oxaliplatin/medicalis | Oxaliplatin/teva | Oxaliplatin/thama | Oxaliplatine/Generics | Oxaliprol | Oxalizor | Oxaviatin | Plaxitin | Rectoxal</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin ebewe | Oxaliplatin hospira | Oxaliplatin teva | Sindoxplatin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin kabi | Oxaliplatin pliva | Sinoxal</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Gessedil | Livellin | Oxaliplatin accord | Oxaliplatin ebewe | Oxaliplatin hospira | Oxaliplatin kabi | Oxaliplatin medac | Oxaliplatin Medico Uno | Oxaliplatin ratiopharm | Oxaliplatin teva | Sinoxal</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Belloxa | Eloxatin | Oxaliplatin actavis | Oxaliplatin medac | Oxitan | Oxitel | Rexta | Sanroxa</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Eloxatine</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adplatin | Celdach | Dacotin | Kinaplat | Lyoplat | Megaplat | Neoxal | Oplatin | Oxa | Oxalip | Oxalispera | Oxaltero | Oxaltor | Oxamil | Oxifect | Oxiplat | Oxitan | Oxitoz | Oxitrust | Oxoplan | Oxosar | Oxpla | Oxyrea | Soxplat | X plat | Xalipat | Xplatin | Xtide | Zolon</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatino | Oxaliplatino accord healthcare | Oxaliplatino Actavis | Oxaliplatino acv | Oxaliplatino AHCL | Oxaliplatino fki | Oxaliplatino hospira | Oxaliplatino MG | Oxaliplatino sandoz | Oxaliplatino sun</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Elplat | Oxaliplatin chemiphar | Oxaliplatin ffp | Oxaliplatin hospira | Oxaliplatin sandoz | Oxaliplatin teva</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Adplatin | Celdach | Eloxatin | Oplatin | Oxalirex | Oxitan | Oxol | X plat | Xalipat | Zildox</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Belloxa | Dong a oxaliplatin | Eloxatin | Foxantal | Ildong oxaliplatin | Kabi oxaliplatin | Liplatin | Newgen oxaliplatin | Nexatin | Oxad | Oxalitin | Oxapla | Oxaplin | Oxp | Oxplatin | Pfizer oxaliplatin | Platinox | Pleoxtin | Rioplatin | Teva oxaliplatin | Tinocxatin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Oxaliplatin ebewe</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Eloxatine | Geneplatin | Oxaliplatin hospira | Oxaliplatine mylan | X plat | Xaliplat</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Gessedil | Oksaliplatina Ebewe | Oksaliplatina medac | Oxaliplatin accord | Oxaliplatin actavis | Oxaliplatin csc | Oxaliplatin hospira | Oxaliplatin kabi | Oxaliplatin Mylan | Oxaliplatin strides | Oxaliplatin teva</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Eloxatine | Oxaliplatin accord | Oxaliplatin actavis | Oxaliplatin hospira | Oxaliplatin kabi | Oxaliplatin pliva</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Oxiplat | Xylatin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Entia | Olipcis | Oxaliplatino | Oxitan | Plaxoten | Recoplat | Riptam | Sylvetec | Tiboquir | Zolaxat | Zunexil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Hovid oxaliplatin | Oxalitin | Oxaplat | Oxaplin</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Celdach | Oxaliplatin sandoz</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin accord | Oxaliplatin fresenius kabi | Oxaliplatin mayne | Oxaliplatine hikma | Oxaliplatine sandoz | Oxaliplatine SUN | Oxaliplatine Winthrop concentraat | Oxalisin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Medaplat | Oksaliplatin sun | Oxaliplatin actavis | Oxaliplatin fresenius kabi | Oxaliplatin mayne | Oxaliplatin teva | Oxaliplatin winthrop</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliccord | Oxaliplatin accord | Oxaliplatin ebewe</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Crisapla | Onicol | Oxaliplatino | Platinostyl</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Biomedis Oxaliplatin | Eloxatin | Henplatin | Hospira Oxaliplatin | Innoxaplin | Oxaplat | Oxavid | Oxitel | Oxuba | Platinox | Sindoxplatin | Vexplatin | Xaliptine | Zildox</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Celdach | Dabenzol | Eloxatin | Geneplatin | Oxabel | Oxaliplatin ebewe | Oxaliplatin liv pharma | Oxaliplatin medac | Oxaliplatino varifarma | Oxalitin | Xaliplatin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Eloxatine | Oxaliplatin actavis | Oxaliplatin hospira | Oxaliplatin kabi | Oxaliplatin medac | Oxaliplatin Mylan | Oxaliplatin teva | Oxaliplatinum Accord | Oxaliplatinum Winthrop Lz</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatina Accord | Oxaliplatina Hospira | Oxaliplatina Kabi | Oxaliplatina Teva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Crisapla | Dabenzol | Dacplat | Fada oxaliplatino | Goxyral | Kebir | Mitog | O plat | Oxaliplatino fusa | Oxaliplatino lasca | Oxaliplatino libra | Oxaliplatino nl pharma | Oxaliplatino sandoz | Oxaliplatino tuteur | Oxaliplatino varifarma | Oxaliplatino vmg | Oxaltie | Xaliplat</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin accord | Oxaliplatin actavis | Oxaliplatin ebewe | Oxaliplatin kabi | Oxaliplatin Medico Uno | Oxaliplatin stada | Oxaliplatina Teva | Rezidol</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Exorum | Flatiplat | Gessedil | Oxaliplatin ebewe | Oxaliplatin Filaxis | Oxaliplatin lachema | Oxaliplatin medac | Oxaliplatin ronc | Oxaliplatin teva | Oxatera | Oxiplat | Oxitan | Platicad | Plaxat | Texaloc</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxitan | Xaliptine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin accord | Oxaliplatin actavis | Oxaliplatin ebewe | Oxaliplatin fresenius kabi | Oxaliplatin hospira | Oxaliplatin medac | Oxaliplatin sun | Oxaliplatin teva | Oxaliplatin vianex | Oxaliplatin winthrop</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin dbl | Oxaliplatin sandoz</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oksaliplatin Kabi | Oksaliplatin lek | Oksaliplatin Teva</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Oxaliplatin kabi | Oxaliplatin medac | Oxaliplatin sandoz | Oxaliplatin stada | Oxaliplatin teva | Oxaliplatina Actavis | Oxaliplatina Hospira | Oxaliplatina Pliva | Oxaliplatina Winthrop | Rezidol | Sinoxal</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Entia | Opatin | Oxalip | Oxaliplatin medac | Oxalsan | Oxaplat | Oxol</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Cytoxaline | Eloxatine | Oxaliplatin actavis | Oxaliplatin ebewe | Oxaliplatine kabi | Xaliplat</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Curatinox | Eloxatin | Linoxa | Oxalidem | Oxalimedac | Oxalpin | Oxatu s | Oxebewe | Platoxatin | Ploxal | Ploxal S</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Eloxatin | Folep | Opatin | Orectalip | Oxalip | Oxaliplatin hospira | Oxaliplatin Mylan | Oxitan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Eloxameda | Eloxatin | Medaxa | Oxaliplatin accord | Oxaliplatin amaxa | Oxaliplatinum | Oxatera | Oxol | Residol</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Oxol | Xalipat</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Crisapla | Dabenzol | Oxaliplatino | Oxaliplatino delta farma | Oxaliplatino glenmark | Plusplatin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Oxaliplatino</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Atitein | Sunoxiplat</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord Oxaliplatin | Eloplat | Eloxatin | Exiplat | Intas Oxaliplatin | Oplaxin | Oxaliplatin key | Oxaliwin | Recotaxin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Oxaliplatino</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Oxol</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33976624">
<a name="33976624"></a>Ah-Thiane L, Raoul JL, Hiret S, Senellart H, Dumont F, Raimbourg J. Transient vision loss - a rare oxaliplatin-induced ophthalmologic side effect: a report of two cases. <i>Case Rep Oncol</i>. 2021;14(1):483-486. doi:10.1159/000514656<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/33976624/pubmed" id="33976624" target="_blank">33976624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18669868">
<a name="18669868"></a>Al-Batran SE, Hartmann JT, Hofheinz R, et al. Biweekly Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) for Patients With Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction: A Phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie. <i>Ann Oncol</i>. 2008;19(11):1882-1887.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18669868/pubmed" id="18669868" target="_blank">18669868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30982686">
<a name="30982686"></a>Al-Batran SE, Homann N, Pauligk C, et al; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. <i>Lancet</i>. 2019;393(10184):1948-1957. doi:10.1016/S0140-6736(18)32557-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/30982686/pubmed" id="30982686" target="_blank">30982686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17823107">
<a name="17823107"></a>Andre P, Cisternino S, Roy AL, et al. Stability of Oxaliplatin in Infusion Bags Containing 5% Dextrose Injection. <i>Am J Health Syst Pharm</i>. 2007;64(18):1950-1954.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/17823107/pubmed" id="17823107" target="_blank">17823107</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15175436">
<a name="15175436"></a>Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. <i>N Engl J Med</i>. 2004;350(23):2343-2351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/15175436/pubmed" id="15175436" target="_blank">15175436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19451431">
<a name="19451431"></a>Andre T, Boni C, Navarro M, et al. Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. <i>J Clin Oncol</i>. 2009;27(19):3109-3116.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/19451431/pubmed" id="19451431" target="_blank">19451431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15319238">
<a name="15319238"></a>Andre T, Tournigand C, Rosmorduc O, et al. Gemcitabine Combined With Oxaliplatin (GEMOX) in Advanced Biliary Tract Adenocarcinoma: A GERCOR Study. <i>Ann Oncol</i>. 2004;15(9):1339-1343.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/15319238/pubmed" id="15319238" target="_blank">15319238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16937105">
<a name="16937105"></a>Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours. <i>Cancer Chemother Pharmacol</i>. 2007;59(5):637-642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/16937105/pubmed" id="16937105" target="_blank">16937105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27247216">
<a name="27247216"></a>Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2016;34(22):2654-2668. doi:10.1200/JCO.2016.67.5561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/27247216/pubmed" id="27247216" target="_blank">27247216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26846320">
<a name="26846320"></a>Balzer MS, Eggers H, Heuser M, Reising A, Bertram A. Oxaliplatin pharmacokinetics on hemodialysis in a patient with diffuse large B cell lymphoma. <i>Ann Hematol.</i> 2016;95(4):649-650. doi:10.1007/s00277-016-2607-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/26846320/pubmed" id="26846320" target="_blank">26846320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22226517">
<a name="22226517"></a>Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. <i>Lancet</i>. 2012;379(9813):315-321. doi:10.1016/S0140-6736(11)61873-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/22226517/pubmed" id="22226517" target="_blank">22226517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20658614">
<a name="20658614"></a>Beaty O 3rd, Berg S, Blaney S, et al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a children's oncology group study. <i>Pediatr Blood Cancer</i>. 2010;55:440-445.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/20658614/pubmed" id="20658614" target="_blank">20658614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8918492">
<a name="8918492"></a>Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al. Biweekly Intensified Ambulatory Chronomodulated Chemotherapy With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Metastatic Colorectal Cancer. <i>J Clin Oncol</i>. 1996;14(11):2950-2958.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/8918492/pubmed" id="8918492" target="_blank">8918492</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14692042">
<a name="14692042"></a>Bhargava P, Gammon D, McCormick MJ. Hypersensitivity and Idiosyncratic Reactions to Oxaliplatin. <i>Cancer</i>. 2004;100(1):211-212.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/14692042/pubmed" id="14692042" target="_blank">14692042</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18006893">
<a name="18006893"></a>Bokemeyer C, Oechsle K, Honecker F, et al. Combination Chemotherapy With Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Cisplatin-Refractory or Multiply Relapsed Germ-Cell Tumors: A Study of the German Testicular Cancer Study Group. <i>Ann Oncol</i>. 2008;19(3):448-453.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18006893/pubmed" id="18006893" target="_blank">18006893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12888815">
<a name="12888815"></a>Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity Reactions Related to Oxaliplatin (OHP). <i>Br J Cancer</i>. 2003;89(3):477-481.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/12888815/pubmed" id="12888815" target="_blank">12888815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16549810">
<a name="16549810"></a>Carneiro BA, Kaminer L, Eldibany M, Sreekantaiah C, Kaul K, Locker GY. Oxaliplatin-related acute myelogenous leukemia. <i>Oncologist</i>. 2006;11(3):261-262. doi:10.1634/theoncologist.11-3-261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/16549810/pubmed" id="16549810" target="_blank">16549810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12422304">
<a name="12422304"></a>Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. <i>Semin Oncol</i>. 2002;29(5 Suppl 15):11-20. doi:10.1053/sonc.2002.35524<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/12422304/pubmed" id="12422304" target="_blank">12422304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18421053">
<a name="18421053"></a>Cassidy J, Clarke S, Díaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. <i>J Clin Oncol</i>. 2008;26(12):2006-2012. doi:10.1200/JCO.2007.14.9898<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18421053/pubmed" id="18421053" target="_blank">18421053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27072569">
<a name="27072569"></a>Cercek A, Park V, Yaeger R, et al. Faster FOLFOX: Oxaliplatin can be safely infused at a rate of 1 mg/m<sup>2</sup>/min. <i>J Oncol Pract</i>. 2016;12(5):e548-e553. doi:10.1200/JOP.2015.008417<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/27072569/pubmed" id="27072569" target="_blank">27072569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15590869">
<a name="15590869"></a>Cersosimo RJ. Oxaliplatin-Associated Neuropathy: A Review. <i>Ann Pharmacother</i>. 2005;39(1):128-135.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/15590869/pubmed" id="15590869" target="_blank">15590869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26920385">
<a name="26920385"></a>Charrier T, Passot G, Peron J, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. <i>Ann Surg Oncol</i>. 2016;23(7):2315-2322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/26920385/pubmed" id="26920385" target="_blank">26920385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21561347">
<a name="21561347"></a>Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX Versus Gemcitabine for Metastatic Pancreatic Cancer. <i>N Engl J Med</i>. 2011;364(19):1817-1825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21561347/pubmed" id="21561347" target="_blank">21561347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575490">
<a name="30575490"></a>Conroy T, Hammel P, Hebbar M, et al; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer. <i>N Engl J Med</i>. 2018;379(25):2395-2406. doi:10.1056/NEJMoa1809775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/30575490/pubmed" id="30575490" target="_blank">30575490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20940718">
<a name="20940718"></a>Conroy T, Yataghène Y, Etienne PL, et al. Phase II Randomised Trial of Chemoradiotherapy With FOLFOX4 or Cisplatin Plus Fluorouracil in Oesophageal Cancer. <i>Br J Cancer</i>. 2010;103(9):1349-1355.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/20940718/pubmed" id="20940718" target="_blank">20940718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26338525">
<a name="26338525"></a>Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. <i>Lancet Oncol</i>. 2015;16(13):1306-1315. doi:10.1016/S1470-2045(15)00122-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/26338525/pubmed" id="26338525" target="_blank">26338525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16757095">
<a name="16757095"></a>De Giorgi U, Rosti G, Aieta M, et al. Phase II Study of Oxaliplatin and Gemcitabine Salvage Chemotherapy in Patients With Cisplatin-Refractory Nonseminomatous Germ Cell Tumor. <i>Eur Urol</i>. 2006;50(5):1032-1038.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/16757095/pubmed" id="16757095" target="_blank">16757095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10944126">
<a name="10944126"></a>de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. <i>J Clin Oncol</i>. 2000;18(16):2938-2947. doi:10.1200/JCO.2000.18.16.2938<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/10944126/pubmed" id="10944126" target="_blank">10944126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16595069">
<a name="16595069"></a>de Lemos ML, Walisser S. Management of Extravasation of Oxaliplatin. <i>J Oncol Pharm Pract</i>. 2005;11(4):159-162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/16595069/pubmed" id="16595069" target="_blank">16595069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11886003">
<a name="11886003"></a>Dieras V, Bougnoux P, Petit T, et al. Multicentre Phase II Study of Oxaliplatin as a Single-Agent in Cisplatin/Carboplatin +/- Taxane-Pretreated Ovarian Cancer Patients. <i>Ann Oncol</i>. 2002;13(2):258-266.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/11886003/pubmed" id="11886003" target="_blank">11886003</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14523790">
<a name="14523790"></a>Doroshow JH, Synold TW, Gandara D, et al, “Pharmacology of Oxaliplatin in Solid Tumor Patients With Hepatic Dysfunction: A Preliminary Report of the National Cancer Institute Organ Dysfunction Working Group,” <i>Semin Oncol</i>, 2003, 30(4 Suppl 15):14-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/14523790/pubmed" id="14523790" target="_blank">14523790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24718886">
<a name="24718886"></a>Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. <i>Ann Oncol</i>. 2014;25(7):1346-1355. doi:10.1093/annonc/mdu141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24718886/pubmed" id="24718886" target="_blank">24718886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20921465">
<a name="20921465"></a>Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. <i>J Clin Oncol</i>. 2010;28(31):4697-4705. doi:10.1200/JCO.2009.27.4860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/20921465/pubmed" id="20921465" target="_blank">20921465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21427067">
<a name="21427067"></a>Durand JP, Deplanque G, Montheil V, et al. Efficacy of Venlafaxine for the Prevention and Relief of Oxaliplatin-Induced Acute Neurotoxicity: Results of EFFOX, a Randomized, Double-Blind, Placebo-Controlled Phase III Trial. <i>Ann Oncol</i>. 2012;23(1):200-205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21427067/pubmed" id="21427067" target="_blank">21427067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11161414">
<a name="11161414"></a>Earle CC, Chen WY, Ryan DP, Mayer RJ. Oxaliplatin-induced Evan's syndrome. <i>Br J Cancer</i>. 2001;84(3):441. doi:10.1054/bjoc.2000.1608<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/11161414/pubmed" id="11161414" target="_blank">11161414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eloxatin.1">
<a name="Eloxatin.1"></a>Eloxatin (oxaliplatin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eloxatin.1">
<a name="Eloxatin.1"></a>Eloxatin (oxaliplatin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eloxatin.2">
<a name="Eloxatin.2"></a>Eloxatin (oxaliplatin) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17470860">
<a name="17470860"></a>Falcone A, Ricci S, Brunetti I, et al. Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) as First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest. <i>J Clin Oncol</i>. 2007;25(13):1670-1676.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/17470860/pubmed" id="17470860" target="_blank">17470860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32222353">
<a name="32222353"></a>Frydenberg H, Harsem NK, Ofigsbø Å, et al. Chemotherapy during pregnancy for advanced colon cancer: a case report [published online ahead of print March 6, 2020]. <i>Clin Colorectal Cancer</i>. 2020;S1533-0028(20)30036-0. doi:10.1016/j.clcc.2020.02.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/32222353/pubmed" id="32222353" target="_blank">32222353</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20943374">
<a name="20943374"></a>Geoerger B, Chisholm J, Deley ML, et al. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortium Study. <i>European Journal of Cancer</i>. 2011;47:230-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/20943374/pubmed" id="20943374" target="_blank">20943374</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25314931">
<a name="25314931"></a>Gori S, Lunardi G, Inno A, et al. Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis. <i>Clin Colorectal Cancer.</i> 2014;13(4):260-263. doi:10.1016/j.clcc.2014.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/25314931/pubmed" id="25314931" target="_blank">25314931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021:39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21189381">
<a name="21189381"></a>Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7. <i>J Clin Oncol.</i> 2011;29(4):421-427.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21189381/pubmed" id="21189381" target="_blank">21189381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29590544">
<a name="29590544"></a>Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. <i>N Engl J Med</i>. 2018;378(13):1177-1188. doi:10.1056/NEJMoa1713709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/29590544/pubmed" id="29590544" target="_blank">29590544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20209610">
<a name="20209610"></a>Hainsworth JD, Spigel DR, Burris HA 3rd, et al. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. <i>Cancer</i>. 2010;116(10):2448-2454.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/20209610/pubmed" id="20209610" target="_blank">20209610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hall.1">
<a name="Hall.1"></a>Hall PS, Swinson D, Waters JS, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): the GO2 phase III trial [Abstract 4006 from 2019 ASCO annual meeting]. <i>J Clin Oncol. </i>2019;37(suppl):4006.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21383294">
<a name="21383294"></a>Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. <i>J Clin Oncol. </i>2011;29(11):1465-1471. doi:10.1200/JCO.2010.33.6297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21383294/pubmed" id="21383294" target="_blank">21383294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27904744">
<a name="27904744"></a>Hancox JC, Caves RE, Choisy SC, James AF. QT interval prolongation and torsades de pointes with oxaliplatin. <i>Ther Adv Drug Saf</i>. 2016;7(6):261-263. doi:10.1177/2042098616666081<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/27904744/pubmed" id="27904744" target="_blank">27904744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29578402">
<a name="29578402"></a>Hann A, Nosalski E, Hermann PC, Egger J, Seufferlein T, Keller F. Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review. <i>Clin Nephrol.</i> 2018;90(2):125-141. doi:10.5414/CN109327<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/29578402/pubmed" id="29578402" target="_blank">29578402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21572345">
<a name="21572345"></a>Hartmann C, Weinel P, Schmid H, et al. Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children. <i>J Pediatr Hematol Oncol</i>. 2011;33(5):344-349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21572345/pubmed" id="21572345" target="_blank">21572345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18640933">
<a name="18640933"></a>Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. <i>J Clin Oncol.</i> 2008;26(21):3523-3529. doi:10.1200/JCO.2007.15.4138<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18640933/pubmed" id="18640933" target="_blank">18640933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21499694">
<a name="21499694"></a>Horimatsu T, Miyamoto S, Morita S, et al. Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. <i>Cancer Chemother Pharmacol.</i> 2011;68(1):263-266. doi:10.1007/s00280-011-1633-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21499694/pubmed" id="21499694" target="_blank">21499694</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28536826">
<a name="28536826"></a>Horimatsu T, Nakayama N, Moriwaki T, et al. A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. <i>Int J Clin Oncol</i>. 2017;22(5):905-912. doi:10.1007/s10147-017-1138-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/28536826/pubmed" id="28536826" target="_blank">28536826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26905139">
<a name="26905139"></a>Jain A, Dubashi B, Parameswaran S, Ganesh RN. Oxaliplatin induced acute tubular necrosis. <i>Indian J Cancer</i>. 2015;52(3):363-364. doi:10.4103/0019-509X.176696<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/26905139/pubmed" id="26905139" target="_blank">26905139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34912120">
<a name="34912120"></a>Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. <i>Nature</i>. 2021a;600(7890):727-730. doi:10.1038/s41586-021-04161-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/34912120/pubmed" id="34912120" target="_blank">34912120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34102137">
<a name="34102137"></a>Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <i>Lancet</i>. 2021b;398(10294):27-40. doi:10.1016/S0140-6736(21)00797-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/34102137/pubmed" id="34102137" target="_blank">34102137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118214">
<a name="20118214"></a>Janus N, Thariat J, Boulanger H, et al. Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients. <i>Ann Oncol</i>. 2010;21(7):1395-1403.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/20118214/pubmed" id="20118214" target="_blank">20118214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24339718">
<a name="24339718"></a>Kang GH, Moon HS, Lee ES, et al. A case of liver fibrosis with splenomegaly after oxaliplatin-based adjuvant chemotherapy for colon cancer. <i>J Korean Med Sci</i>. 2013;28(12):1835-1838. doi:10.3346/jkms.2013.28.12.1835<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24339718/pubmed" id="24339718" target="_blank">24339718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21892270">
<a name="21892270"></a>Katsumata K, Sumi T, Wada T, et al. Oxaliplatin for metastatic colon cancer in a patient with renal failure. <i>Clin Med Oncol</i>. 2008;2:97-101. doi:10.4137/cmo.s412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21892270/pubmed" id="21892270" target="_blank">21892270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31180816">
<a name="31180816"></a>Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2019;37(23):2082-2088. doi:10.1200/JCO.19.00946<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/31180816/pubmed" id="31180816" target="_blank">31180816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12065561">
<a name="12065561"></a>Khushalani NI, Leichman CG, Proulx G, et al. Oxaliplatin in Combination with Protracted-Infusion Fluorouracil and Radiation: Report of a Clinical Trial for Patients With Esophageal Cancer. <i>J Clin Oncol</i>. 2002;20(12):2844-2850.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/12065561/pubmed" id="12065561" target="_blank">12065561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19246947">
<a name="19246947"></a>Kim BH, Bradley T, Tai J, et al. Hypersensitivity to Oxaliplatin: An Investigation of Incidence and Risk Factors, and Literature Review. <i>Oncology</i>. 2009;76(4):231-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/19246947/pubmed" id="19246947" target="_blank">19246947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33234775">
<a name="33234775"></a>Kim SB, Kim SY, Kim KH, Kim TN. Oxaliplatin-induced sudden hearing loss in a patient with pancreatic cancer. <i>Korean J Gastroenterol</i>. 2020;76(5):261-264. doi:10.4166/kjg.2020.121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/33234775/pubmed" id="33234775" target="_blank">33234775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32071259">
<a name="32071259"></a>Klipstein S, Fallat ME, Savelli S; Committee on Bioethics; Section on Hematology/Oncology; Section on Surgery. Fertility preservation for pediatric and adolescent patients with cancer: medical and ethical considerations. <i>Pediatrics</i>. 2020;145(3):e20193994. doi:10.1542/peds.2019-3994<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/32071259/pubmed" id="32071259" target="_blank">32071259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21067912">
<a name="21067912"></a>Knijn N, Tol J, Koopman M, et al. The Effect of Prophylactic Calcium and Magnesium Infusions on the Incidence of Neurotoxicity and Clinical Outcome of Oxaliplatin-Based Systemic Treatment in Advanced Colorectal Cancer Patients. <i>Eur J Cancer</i>. 2011;47(3):369-374.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21067912/pubmed" id="21067912" target="_blank">21067912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14701772">
<a name="14701772"></a>Kollmannsberger C, Beyer J, Liersch R, et al. Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group. <i>J Clin Oncol</i>. 2004;22(1):108-114.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/14701772/pubmed" id="14701772" target="_blank">14701772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35702554">
<a name="35702554"></a>Kozai L, Benavente K, Obeidat A, Acoba J. FOLFOXIRI in pregnant women with colorectal cancer: a case report and review of the literature. <i>Case Rep Oncol</i>. 2022;15(1):447-454. doi:10.1159/000524325<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/35702554/pubmed" id="35702554" target="_blank">35702554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14581435">
<a name="14581435"></a>Kretzschmar A, Pink D, Thuss-Patience P, Dörken B, Reichert P, Eckert R. Extravasations of oxaliplatin. <i>J Clin Oncol</i>. 2003;21(21):4068-4069. doi:10.1200/JCO.2003.99.095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/14581435/pubmed" id="14581435" target="_blank">14581435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37093108">
<a name="37093108"></a>Krutsch K, Adams K, Shinwari M, Baucom RB. Persistence of oxaliplatin transfer into human milk: a case report. <i>Breastfeed Med</i>. Published April 21, 2023. doi:10.1089/bfm.2023.0037<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/37093108/pubmed" id="37093108" target="_blank">37093108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17470851">
<a name="17470851"></a>Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. <i>J Clin Oncol. </i>2007;25(16):2198-2204. doi:10.1200/JCO.2006.08.2974<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/17470851/pubmed" id="17470851" target="_blank">17470851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24942022">
<a name="24942022"></a>Lam CG, Furman WL, Wang C, et al. Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors. <i>J Pediatr Hematol Oncol</i>. 2015;37(1):e13-e18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24942022/pubmed" id="24942022" target="_blank">24942022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33798493">
<a name="33798493"></a>Lamarca A, Palmer DH, Wasan HS, et al; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. <i>Lancet Oncol.</i> 2021;22(5):690-701. doi:10.1016/S1470-2045(21)00027-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/33798493/pubmed" id="33798493" target="_blank">33798493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32976936">
<a name="32976936"></a>Lambertini M, Peccatori FA, Demeestere I, et al; ESMO Guidelines Committee. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO clinical practice guidelines. <i>Ann Oncol</i>. 2020;31(12):1664-1678. doi:10.1016/j.annonc.2020.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/32976936/pubmed" id="32976936" target="_blank">32976936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10668856">
<a name="10668856"></a>Levi F, Metzger G, Massari C, et al. Oxaliplatin: Pharmacokinetics and Chronopharmacological Aspects. <i>Clin Pharmacokinet</i>. 2000, 38(1):1-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/10668856/pubmed" id="10668856" target="_blank">10668856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26443807">
<a name="26443807"></a>Levi M, Shalgi R, Brenner B, et al. The impact of oxaliplatin on the gonads: from bedside to the bench. <i>Mol Hum Reprod</i>. 2015;21(12):885-893. doi:10.1093/molehr/gav055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/26443807/pubmed" id="26443807" target="_blank">26443807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30986117">
<a name="30986117"></a>Lieu C, Kennedy EB, Bergsland E, et al. Duration of oxaliplatin-containing adjuvant therapy for stage III colon cancer: ASCO Clinical Practice Guideline [published online April 15, 2019]. <i>J Clin Oncol</i>. 2019:JCO1900281. doi:10.1200/JCO.19.00281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/30986117/pubmed" id="30986117" target="_blank">30986117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18005385">
<a name="18005385"></a>López A, Gutiérrez A, Palacios A, et al. GEMOX-R Regimen is a Highly Effective Salvage Regimen in Patients With Refractory/Relapsing Diffuse Large-Cell Lymphoma: A Phase II Study. <i>Eur J Haematol</i>. 2008;80(2):127-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18005385/pubmed" id="18005385" target="_blank">18005385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24297951">
<a name="24297951"></a>Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). <i>J Clin Oncol</i>. 2014;32(10):997-1005. doi:10.1200/JCO.2013.52.0536<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24297951/pubmed" id="24297951" target="_blank">24297951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25337750">
<a name="25337750"></a>Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. <i>N Engl J Med</i>. 2014;371(17):1609-1618. doi:10.1056/NEJMoa1403108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/25337750/pubmed" id="25337750" target="_blank">25337750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23024067">
<a name="23024067"></a>Macy ME, Duncan T, Whitlock J, et al. A multi-center phase 1b study of oxaliplatin (NSC #266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. <i>Pediatric Blood Cancer</i>. 2013;60:230-236.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/23024067/pubmed" id="23024067" target="_blank">23024067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32066346">
<a name="32066346"></a>Maruta M, Miyoshi T, Matsuo N, et al. Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer. <i>J Chemother.</i> 2021;33(1):51-55. doi:10.1080/1120009X.2020.1728861<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/32066346/pubmed" id="32066346" target="_blank">32066346</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23335436">
<a name="23335436"></a>Mascarenhas L, Malogolowkin M, Armenian SH, Sposto R, Venkatramani R. A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors. <i>Pediatric Blood Cancer</i>. 2013;60:1103-1107. doi:10.1002/pbc.24471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/23335436/pubmed" id="23335436" target="_blank">23335436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10663631">
<a name="10663631"></a>Massari C, Brienza S, Rotarski M, et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function.<i> Cancer Chemother Pharmacol.</i> 2000;45(2):157-164. doi:10.1007/s002800050024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/10663631/pubmed" id="10663631" target="_blank">10663631</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19117350">
<a name="19117350"></a>McGregor LM, Spunt SL, Santana VM, et al. Phase I study of an oxaliplatin-etoposide regimen in pediatric patients with recurrent solid tumors. <i>Cancer</i>. 2009;115(3):655-664.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/19117350/pubmed" id="19117350" target="_blank">19117350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21151636">
<a name="21151636"></a>Mesquida M, Sanchez-Dalmau B, Ortiz-Perez S, et al. Oxaliplatin-related ocular toxicity. <i>Case Rep Oncol</i>. 2010;3(3):423-427. doi:10.1159/000322675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21151636/pubmed" id="21151636" target="_blank">21151636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, et al. Management of Uncommon Chemotherapy-Induced Emergencies. <i>Lancet Oncol</i>. 2011;12(8):806-814.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nagatani.1">
<a name="Nagatani.1"></a>Nagatani Y, Imamura Y, Nakamura T, et al. Pharmacokinetics of oxaliplatin in a hemodialysis patient with metastatic colon cancer.<i> Int J Oncol Res</i>. 2019;2(2):1-5. doi:org/10.23937/2643-4563/1710017</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24736875">
<a name="24736875"></a>National Toxicology Program. NTP Monograph: Developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy. <i>NTP Monogr</i>. 2013;(2):i-214.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24736875/pubmed" id="24736875" target="_blank">24736875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12232749">
<a name="12232749"></a>Nehls O, Klump B, Arkenau HT, et al. Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial.<i> Br J Cancer.</i> 2002;87(7):702-704. doi:10.1038/sj.bjc.6600543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/12232749/pubmed" id="12232749" target="_blank">12232749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18182984">
<a name="18182984"></a>Nehls O, Oettle H, Hartmann JT, et al. Capecitabine Plus Oxaliplatin as First-Line Treatment in Patients With Advanced Biliary System Adenocarcinoma: A Prospective Multicentre Phase II Trial. <i>Br J Cancer</i>. 2008;98(2):309-315.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18182984/pubmed" id="18182984" target="_blank">18182984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35914638">
<a name="35914638"></a>Obermannová R, Alsina M, Cervantes A, et al; ESMO Guidelines Committee. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. <i>Ann Oncol.</i> 2022;33(10):992-1004. doi:10.1016/j.annonc.2022.07.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/35914638/pubmed" id="35914638" target="_blank">35914638</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21704446">
<a name="21704446"></a>Oechsle K, Kollmannsberger C, Honecker F, et al .Long-Term Survival After Treatment With Gemcitabine and Oxaliplatin With and Without Paclitaxel Plus Secondary Surgery in Patients With Cisplatin-Refractory and/or Multiply Relapsed Germ Cell Tumors. <i>Eur Urol</i>. 2011;60(4):850-855.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21704446/pubmed" id="21704446" target="_blank">21704446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24982456">
<a name="24982456"></a>Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. <i>J Clin Oncol.</i> 2014;32(23):2423-2429. doi:10.1200/JCO.2013.53.6995<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24982456/pubmed" id="24982456" target="_blank">24982456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24216561">
<a name="24216561"></a>Oh SY, Wasif N, Garcon MC, Rodriguez G, Saif MW. Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. <i>JOP</i>. 2013;14(6):676-679. doi:10.6092/1590-8577/1629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24216561/pubmed" id="24216561" target="_blank">24216561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32670652">
<a name="32670652"></a>Okamoto T, Takagi K, Fukuda K. Oxaliplatin-induced Lhermitte's sign in gastric cancer. <i>Case Rep Oncol Med</i>. 2020;2020:8826657. doi:10.1155/2020/8826657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/32670652/pubmed" id="32670652" target="_blank">32670652</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620997">
<a name="29620997"></a>Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(19):1994-2001. doi:10.1200/JCO.2018.78.1914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/29620997/pubmed" id="29620997" target="_blank">29620997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24901360">
<a name="24901360"></a>OʼReilly EM, Perelshteyn A, Jarnagin WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. <i>Ann Surg</i>. 2014;260(1):142-148.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24901360/pubmed" id="24901360" target="_blank">24901360</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Osawa.1">
<a name="Osawa.1"></a>Osawa H. Oxaliplatin pharmacokinetics and pharmacodynamics in three metastatic colorectal cancer patients with hemodialysis. <i>J Mol Genet Med</i>. 2016;10:234. doi:10.4172/1747-0862.1000234</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19164203">
<a name="19164203"></a>Overman MJ, Varadhachary GR, Kopetz S, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. <i>J Clin Oncol</i>. 2009;27(16):2598-2603. doi:10.1200/JCO.2008.19.7145<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/19164203/pubmed" id="19164203" target="_blank">19164203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Oxaliplatin [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; January 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nextgen.1">
<a name="Nextgen.1"></a>Oxaliplatin [prescribing information]. Brooklyn, NY: Nextgen Pharmaceuticals Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.1">
<a name="Pfizer.1"></a>Oxaliplatin [product monograph]. Woodbridge, Ontario, Canada: Auro Pharma Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29855806">
<a name="29855806"></a>Papaxoinis G, Kotoula V, Giannoulatou E, et al. Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. <i>Med Oncol</i>. 2018;35(7):101. doi:10.1007/s12032-018-1160-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/29855806/pubmed" id="29855806" target="_blank">29855806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160‐vi170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14998855">
<a name="14998855"></a>Pectasides D, Pectasides M, Farmakis D, et al. Gemcitabine and Oxaliplatin (GEMOX) in Patients With Cisplatin-Refractory Germ Cell Tumors: A Phase II Study. <i>Ann Oncol</i>. 2004;15(3):493-497.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/14998855/pubmed" id="14998855" target="_blank">14998855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21565490">
<a name="21565490"></a>Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-Study Group. <i>Eur J Cancer.</i> 2011;47(11):1676-1681. doi:10.1016/j.ejca.2011.04.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/21565490/pubmed" id="21565490" target="_blank">21565490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22997449">
<a name="22997449"></a>Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23(suppl 7):167-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/22997449/pubmed" id="22997449" target="_blank">22997449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33299623">
<a name="33299623"></a>Petruzzelli P, Zizzo R, Tavassoli E, et al. Colon adenocarcinoma during pregnancy: a case report and review of the literature. <i>Case Rep Obstet Gynecol</i>. 2020;2020:8894722. doi:10.1155/2020/8894722<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/33299623/pubmed" id="33299623" target="_blank">33299623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10715288">
<a name="10715288"></a>Piccart MJ, Green JA, Lacave AJ, et al. Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group. <i>J Clin Oncol</i>. 2000;18(6):1193-1202.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/10715288/pubmed" id="10715288" target="_blank">10715288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30996068">
<a name="30996068"></a>Pissarra A, Malheiro M, Matos LV, Plácido AN. Severe rhabdomyolysis related to oxaliplatin adjuvant therapy for colorectal cancer. <i>BMJ Case Rep</i>. 2019;12(4):e228673. doi:10.1136/bcr-2018-228673<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/30996068/pubmed" id="30996068" target="_blank">30996068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19033714">
<a name="19033714"></a>Polyzos A, Tsavaris N, Gogas H, et al. Clinical Features of Hypersensitivity Reactions to Oxaliplatin: A 10-Year Experience. <i>Oncology</i>. 2009;76(1):36-41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/19033714/pubmed" id="19033714" target="_blank">19033714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24474925">
<a name="24474925"></a>Quack H, Erpenbeck L, Wolff HA, et al. Oxaliplatin-induced leukocytoclastic vasculitis under adjuvant chemotherapy for colorectal cancer: two cases of a rare adverse event. <i>Case Rep Oncol</i>. 2013;6(3):609-615. doi:10.1159/000357166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24474925/pubmed" id="24474925" target="_blank">24474925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19887466">
<a name="19887466"></a>Ramanathan PK, Rothenberg ML, de Gramont A, et al .Incidence and Evolution of Oxaliplatin-Induced Peripheral Sensory Neuropathy in Diabetic Patients With Colorectal Cancer: A Pooled Analysis of Three Phase III Studies. <i>Ann Oncol</i>. 2010;21(4):754-758.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/19887466/pubmed" id="19887466" target="_blank">19887466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17990179">
<a name="17990179"></a>Rodríguez J, Gutierrez A, Palacios A, et al. Rituximab, Gemcitabine and Oxaliplatin: An Effective Regimen in Patients With Refractory and Relapsing Mantle Cell Lymphoma. <i>Leuk Lymphoma</i>. 2007;48(11):2172-2178.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/17990179/pubmed" id="17990179" target="_blank">17990179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22102978">
<a name="22102978"></a>Ryu CG, Jung EJ, Kim G, Kim SR, Hwang DY. Oxaliplatin-induced pulmonary fibrosis: two case reports. <i>J Korean Soc Coloproctol</i>. 2011;27(5):266-269. doi:10.3393/jksc.2011.27.5.266<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/22102978/pubmed" id="22102978" target="_blank">22102978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35303936">
<a name="35303936"></a>Saad R, Hannun A, Temraz S, Finianos A, Zeenny RM. Oxaliplatin-induced thrombotic microangiopathy: a case report. <i>J Med Case Rep</i>. 2022;16(1):110. doi:10.1186/s13256-022-03309-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/35303936/pubmed" id="35303936" target="_blank">35303936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18421054">
<a name="18421054"></a>Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. <i>J Clin Oncol.</i> 2008;26(12):2013-2019. doi:10.1200/JCO.2007.14.9930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18421054/pubmed" id="18421054" target="_blank">18421054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31243213">
<a name="31243213"></a>Sasaki K, Zhou Q, Matsumoto Y, Saiki T, Moriyama M, Saijo Y. Treatment of gastric and gastroesophageal cancer patients with hemodialysis by CapeOX. <i>Intern Med</i>. 2019;58(19):2791-2795. doi:10.2169/internalmedicine.2718-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/31243213/pubmed" id="31243213" target="_blank">31243213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24757663">
<a name="24757663"></a>Seo AN, Kim H. Sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy. <i>Clin Mol Hepatol</i>. 2014;20(1):81-84. doi:10.3350/cmh.2014.20.1.81<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24757663/pubmed" id="24757663" target="_blank">24757663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32568633">
<a name="32568633"></a>Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. <i>J Clin Oncol</i>. 2020;38(23):2677-2694. doi:10.1200/JCO.20.00866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/32568633/pubmed" id="32568633" target="_blank">32568633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20855823">
<a name="20855823"></a>Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. <i>J Clin Oncol.</i> 2010;28(30):4581-4586. doi:10.1200/JCO.2010.29.3605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/20855823/pubmed" id="20855823" target="_blank">20855823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Shi.1">
<a name="Shi.1"></a>Shi Q, Sobrero AF, Shields AF, et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. <i>J Clin Oncol</i>. 2017;35(suppl): LBA1 [Abstract LBA1 from 2017 ASCO annual meeting].</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31361914">
<a name="31361914"></a>Smith ZR, Horng M, Rech MA. Medication-induced hyperlactatemia and lactic acidosis: a systematic review of the literature. <i>Pharmacotherapy</i>. 2019;39(9):946-963.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/31361914/pubmed" id="31361914" target="_blank">31361914</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32861308">
<a name="32861308"></a>Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. <i>Lancet</i>. 2020;396(10251):635-648. doi:10.1016/S0140-6736(20)31288-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/32861308/pubmed" id="32861308" target="_blank">32861308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32755482">
<a name="32755482"></a>Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. <i>J Clin Oncol</i>. Published online August 5, 2020. doi:10.1200/JCO.20.01364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/32755482/pubmed" id="32755482" target="_blank">32755482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19149322">
<a name="19149322"></a>Suenaga M, Mizunuma N, Shinozaki E, et al. Management of Allergic Reactions to Oxaliplatin in Colorectal Cancer Patients. <i>J Support Oncol</i>. 2008;6(8):373-378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/19149322/pubmed" id="19149322" target="_blank">19149322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17575231">
<a name="17575231"></a>Synold TW, Takimoto CH, Doroshow JH, et al. Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients With Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clin Cancer Res</i>. 2007;13(12):3660-3666.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/17575231/pubmed" id="17575231" target="_blank">17575231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17699862">
<a name="17699862"></a>Takimoto CH, Graham MA, Lockwood G, et al. Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer patients With Impaired Renal Function. <i>Clin Cancer Res</i>. 2007;13(16):4832-4839.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/17699862/pubmed" id="17699862" target="_blank">17699862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12860942">
<a name="12860942"></a>Takimoto CH, Remick SC, Sharma S, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group study. <i>J Clin Oncol</i>. 2003;21(14):2664-2672. doi:10.1200/JCO.2003.11.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/12860942/pubmed" id="12860942" target="_blank">12860942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33827687">
<a name="33827687"></a>Taooka Y, Yoke H, Inata J. Oxaliplatin-related interstitial pneumonia with high-grade fever and relative bradycardia as the presenting signs: a case report. <i>J Med Case Rep</i>. 2021;15(1):153. doi:10.1186/s13256-021-02769-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/33827687/pubmed" id="33827687" target="_blank">33827687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Taro-Oxaliplatin.1">
<a name="Taro-Oxaliplatin.1"></a>Taro-Oxaliplatin (oxaliplatin) [product monograph]. Brampton, Ontario, Canada: Taro Pharmaceuticals Inc; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25551355">
<a name="25551355"></a>Tran HC, Marachelian A, Venkatramani R, Jubran RF, Mascarenhas L. Oxaliplatin and doxorubicin for relapsed or refractory high-risk neuroblastoma. <i>Pediatr Hematol Oncol</i>. 2015;32(1):26-31. doi: 10.3109/08880018.2014.983624.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/25551355/pubmed" id="25551355" target="_blank">25551355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trissel.1">
<a name="Trissel.1"></a>Trissel LA, Saenz CA, Ingram DS, et al. Compatibility Screening of Oxaliplatin During Simulated Y-Site Administration With Other Drugs. <i>J Oncol Pharm Practice</i>. 2002;8(1):33-37.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18182662">
<a name="18182662"></a>Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>J Clin Oncol</i>. 2008;26(2):196-203.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18182662/pubmed" id="18182662" target="_blank">18182662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29315736">
<a name="29315736"></a>van Berlo-van de Laar IRF, Brummelhuis WJ, Imholz ALT, Schellens JH, Huitema ADR, Jansman FGA. Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations.<i> J Clin Pharm Ther</i>. 2018;43(4):574-577. doi:10.1111/jcpt.12661<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/29315736/pubmed" id="29315736" target="_blank">29315736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28632865">
<a name="28632865"></a>Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. <i>JAMA</i>. 2017;317(23):2392-2401. doi:10.1001/jama.2017.7105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/28632865/pubmed" id="28632865" target="_blank">28632865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31689749">
<a name="31689749"></a>Wang D, Li X, Xu L, et al. Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy: a case report. <i>Medicine (Baltimore).</i> 2019;98(44):e17462. doi:10.1097/MD.0000000000017462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/31689749/pubmed" id="31689749" target="_blank">31689749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24748418">
<a name="24748418"></a>Wang Y, Yu YY, Li W, et al. A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. <i>Cancer Chemother Pharmacol</i>. 2014;73(6):1155-1161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/24748418/pubmed" id="24748418" target="_blank">24748418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20085906">
<a name="20085906"></a>Watayo Y, Kuramochi H, Hayashi K, Nakajima G, Kamikozuru H, Yamamoto M. Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis. <i>Jpn J Clin Oncol</i>. 2010;40(4):360-364. doi:10.1093/jjco/hyp176<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/20085906/pubmed" id="20085906" target="_blank">20085906</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17945475">
<a name="17945475"></a>Wilcox BE, Ryu JH, Kalra S. Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: a report of three cases. <i>Respir Med</i>. 2008;102(2):273-279. doi:10.1016/j.rmed.2007.09.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/17945475/pubmed" id="17945475" target="_blank">17945475</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10408744">
<a name="10408744"></a>Wiseman LR, Adkins JC, Plosker GL, et al .Oxaliplatin: A Review of Its Use in the Management of Metastatic Colorectal Cancer. <i>Drugs Aging</i>. 1999;14(6):459-475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/10408744/pubmed" id="10408744" target="_blank">10408744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25544580">
<a name="25544580"></a>Woo HS, Lee KH, Yoon PH, et al. Oxaliplatin-induced immune-mediated thrombocytopenia: A Case Report. <i>Cancer Res Treat</i>. 2015;47(4):949-953. doi:10.4143/crt.2014.052<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/25544580/pubmed" id="25544580" target="_blank">25544580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22481063">
<a name="22481063"></a>Xiang XJ, Liu YW, Zhang L, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. <i>Anticancer Drugs</i>. 2012;23(5):561-566. doi:10.1097/CAD.0b013e328350dd0d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/22481063/pubmed" id="22481063" target="_blank">22481063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18756532">
<a name="18756532"></a>Xiong HQ, Varadhachary GR, Blais JC, et al. Phase 2 Trial of Oxaliplatin Plus Capecitabine (XELOX) as Second-Line Therapy for Patients With Advanced Pancreatic Cancer. <i>Cancer</i>. 2008;113(8):2046-2052.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/18756532/pubmed" id="18756532" target="_blank">18756532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30827015">
<a name="30827015"></a>Yamada S, Yazawa M, Yamamoto M, et al. A case of biopsy-proven oxaliplatin-induced acute tubulointerstitial nephritis with thrombocytopenia and anemia. <i>CEN Case Rep</i>. 2019;8(3):188-193. doi:10.1007/s13730-019-00390-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/30827015/pubmed" id="30827015" target="_blank">30827015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19826418">
<a name="19826418"></a>Yoo C, Hwang JY, Kim JE, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. <i>Br J Cancer</i>. 2009;101(10):1658-1663. doi:10.1038/sj.bjc.6605374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/19826418/pubmed" id="19826418" target="_blank">19826418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20223786">
<a name="20223786"></a>Zaanan A, Costes L, Gauthier M, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. <i>Ann Oncol</i>. 2010;21(9):1786-1793. doi:10.1093/annonc/mdq038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxaliplatin-drug-information/abstract-text/20223786/pubmed" id="20223786" target="_blank">20223786</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10180 Version 441.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
